Search

Your search keyword '"Casaretti R"' showing total 181 results
Start Over Author "Casaretti R"
181 results on '"Casaretti R"'

1. Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

Author

Cardone, C., De Stefano, A., Rosati, G., Cassata, A., Silvestro, L., Borrelli, M., Di Gennaro, E., Romano, C., Nappi, A., Zanaletti, N., Foschini, F., Casaretti, R., Tatangelo, F., Lastoria, S., Raddi, M., Bilancia, D., Granata, V., Setola, S., Petrillo, A., Vitagliano, C., Gargiulo, P., Arenare, L., Febbraro, A., Martinelli, E., Ciardiello, F., Delrio, P., Budillon, A., Piccirillo, M.C., and Avallone, A.

Published
2023
Full Text
View/download PDF

2. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Mangano, S., Tonato, M., Zucca, E., Valsecchi, M.G., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., Dell'Oro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

3. P-68 Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study

Author

Cardone, C., primary, Piccirillo, M., additional, Rosati, G., additional, De Stefano, A., additional, Romano, C., additional, Nappi, A., additional, Zanaletti, N., additional, Foschini, F., additional, Cassata, A., additional, Casaretti, R., additional, Silvestro, L., additional, Tatangelo, F., additional, Lastoria, S., additional, Raddi, M., additional, Bilancia, D., additional, Febbraro, A., additional, Martinelli, E., additional, Ciardiello, F., additional, Delrio, P., additional, Perrone, F., additional, Budillon, A., additional, and Avallone, A., additional

Published
2022
Full Text
View/download PDF

4. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Bajetta, E., Floriani, I., Di Bartolomeo, M., Labianca, R., Falcone, A., Di Costanzo, F., Comella, G., Amadori, D., Pinto, C., Carlomagno, C., Nitti, D., Daniele, B., Mini, E., Poli, D., Santoro, A., Mosconi, S., Casaretti, R., Boni, C., Pinotti, G., Bidoli, P., Landi, L., Rosati, G., Ravaioli, A., Cantore, M., Di Fabio, F., Aitini, E., Marchet, A., Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Poli, D., Mangano, S., Tonato, M., Zucca, E., Valsecchi, MG., Floriani, I., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Bajetta, E., Di Bartolomeo, M., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., DellʼOro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Labianca, R., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Amadori, D., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Falcone, A., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Di Costanzo, F., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Pinto, C., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Daniele, B., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Nitti, D., Marchet, A., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

5. P-198 Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy

Author

Cardone, C., primary, Collina, F., additional, Brogna, M., additional, Casaretti, R., additional, Cassata, A., additional, De Stefano, A., additional, Di Giovanni, I., additional, Nappi, A., additional, Romano, C., additional, Silvestro, L., additional, Viscardi, G., additional, Zanaletti, N., additional, Di Bonito, M., additional, and Avallone, A., additional

Published
2021
Full Text
View/download PDF

16. Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE)

Author

Avallone, A., primary, Delrio, P., additional, Nasti, G., additional, Cassata, A., additional, Silvestro, L., additional, De Stefano, A., additional, Lastoria, S., additional, Casaretti, R., additional, Romano, C., additional, Ottaiano, A., additional, Di gennaro, E., additional, Nappi, A., additional, Maiolino, P., additional, Cavalcanti, E., additional, Petrillo, A., additional, Tatangelo, F., additional, Giannarelli, D., additional, Galon, J., additional, Ascierto, P.A., additional, and Budillon, A., additional

Published
2018
Full Text
View/download PDF

17. Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

Author

Avallone, A., primary, Nasti, G., additional, Rosati, G., additional, Carlomagno, C., additional, Romano, C., additional, Bilancia, D., additional, De Stefano, A., additional, Silvestro, L., additional, Ottaiano, A., additional, Cassata, A., additional, Bianco, F., additional, Izzo, F., additional, Delrio, P., additional, De Gennaro, E., additional, Casaretti, R., additional, Tafuto, S., additional, Albino, V., additional, Pace, U., additional, Lastoria, S., additional, Gallo, C., additional, Budillon, A., additional, and Piccirillo, M., additional

Published
2018
Full Text
View/download PDF

20. A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICOG trial 0802

Author

Casaretti R, Comella P, Carlomagno C, Maiorino L, Greco E, Russo A, Sanna G, Barzelloni ML, Massidda B, Formica V, Serci C, Defraia S, Palmieri G, and Ionta MT

Subjects
prognosis, Gastric cancer, mutation analysis
Abstract

Background: EGFR overexpression occurs in 27-55% of gastroesophageal adenocarcinomas, and correlates with poor prognosis. We aimed to assess the efficacy and safety of the anti-EGFR antibody Panitumumab (PANIT) in addition to Oxaliplatin, 5-FU and Leucovorin (FOLFOX 4) as front-line treatment in patients (pts) with metastatic gastric or gastroesophageal -junction (GEJ) adenocarcinoma. Primary endpoint was response rate (ORR); secondary endpoints were duration of and time to response (DoR and TTR), safety, PFS and OS. Patients and methods: Between October 2009 and July 2013 we enrolled 65 pts with untreated metastatic gastric(80%) and GEJ (20%) adenocarcinoma at 8 referral SICOG centers. Eligible pts were 69% males, median age 62 years (y) (33-82), 60% and 40% ECOG PS 1 and 0, respectively; 72% and 28% presented with synchronous and metachronous metastases, respectively; 69% had nodal plus visceral metastases. Pts received FOLFOX 4 for a maximum of 12 cycles plus PANIT (6 mg/Kg) for a minimum of 4 cycles or until progression or unacceptable toxicity, q1-14. Response was evaluated every 4 cycles according to modified-RECIST criteria, in intention to treat population . Gene expression profiling studies are ongoing. Results: Eleven and 54 (83%) pts received < and = or > than 4 cycles, respectively. Median number of administered FOLFOX cycles was 8 (1-12) and 43% of pts received all 12 planned cycles; median number of administered PANIT cycles was 8 (1-28) and 43% received 12 or more PANIT cycles. ORR was 42%, median TTR was 2 months (m) (1-11); median DoR 8 m(2-19); median PFS 5.6 m (0.6-16.2); median OS 11 m (0.6-46.3); 1 y PFS and 1y OS rates were 11.4% and 42.7%, respectively. Most frequent PANIT-related AEs were skin toxicity, asthenia, diarrhea and mucositis; 3 pts discontinued PANIT, 1 for infusional reaction, 1 for rash G3, 1 for mucositis G3. No PANIT-related deaths occurred. Conclusions: Addition of PANIT to FOLFOX 4 in gastric and GEJ cancer patients seems to be effective and safe, however ongoing tissue gene expression profiling analyses would identify subpopulation of pts benefiting more from anti-EGFR target therapy in this setting.

Published
2015

21. 'Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet'

Author

Comella, P, Casaretti, R, Manzo, R, Sandomenico, C, Licenziato, M, Avallone, A, Franco, L, Massidda, B, Filippelli, G, Putzu, C, Natale, D, Barberis, G, Maiorino, L, PALMERI, Sergio, Cannone, M, Condemi, G, Leo, S, Tafuto, S, Greco, E, Roselli, M, Milia, V, Gambardella, A, Mancarella, S, Di Pinto, G, De Luca, L, Vessia, G., Comella, P, Casaretti, R, Manzo, R, Sandomenico, C, Licenziato, M, Avallone, A, Franco, L, Massidda, B, Filippelli, G, Putzu, C, Natale, D, Barberis, G, Maiorino, L, Palmeri, S, Cannone, M, Condemi, G, Leo, S, Tafuto, S, Greco, E, Roselli, M, Milia, V, Gambardella, A, Mancarella, S, Di Pinto, G, De Luca, L, and Vessia, G

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, Colorectal cancer, Settore MED/06 - Oncologia Medica, Kaplan-Meier Estimate, Gastroenterology, Disease-Free Survival, Capecitabine, Treatment Outcome, Prognosis, Aged, 80 and over, Retrospective Studies, Randomized Controlled Trials as Topic, Middle Aged, Colorectal Neoplasms, Female, Humans, Quality of Life, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase III as Topic, Aged, Health Status Indicators, Multicenter Studies as Topic, Folinic acid, Quality of life, Internal medicine, 80 and over, medicine, Overall survival, Clinical Trials, Radiology, Nuclear Medicine and imaging, neoplasms, metastatic colorectal cancer,oxaliplatin, physical functioning status, business.industry, Hematology, General Medicine, medicine.disease, Surgery, Oxaliplatin, Phase III as Topic, Oncology, Quartile, business, medicine.drug
Abstract

BACKGROUND: No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine. METHODS: We investigated the independent effect of baseline clinical characteristics and physical functioning (PF) domain on RR, PFS, and OS in 310 patients who completed the EORTC QLQ-C30 questionnaire. Multivariate analyses stratified by treatment were performed. An exploratory analysis was done by grouping patients with a PF score superior or equal to the highest quartile (n = 111), included between the highest and the lowest quartiles (n = 99), or inferior to the lowest quartile (n = 100). The relationship between these three groups and the ECOG PS was then analysed. RESULTS: At multivariate analysis, OS was negatively affected by the number of metastatic sites, the serum alkaline phosphatase, and the ECOG PS, while it was positively affected by the previous surgical resection of the primary tumour. Adding the baseline PF score, the number of disease sites (p < 0.0001), the serum alkaline phosphatase (p = 0.0057), and the PF (p = 0.0007) retained an independent significance, while the ECOG PS and the previous surgery were no longer significant. PF did not significantly affect PFS or RR. A good but not totally overlapping correlation was found between PF grouping and ECOG PS score. CONCLUSIONS: Baseline self-reported PF independently predicted the OS of patients. Assessment of QoL should be incorporated in randomised trials evaluating the management of patients with MCRC.

Published
2010

22. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401

Author

COMELLA P, MASSIDDA B, FILIPPELLI G, FARRIS A, NATALE D, BARBERIS G, MAIORINO L, PALMERI S, CANNONE M, CONDEMI G, SOUTHERN ITALY COOPERATIVE ONCOLOGY GROUP, COLLABORATORS CASARETTI R, SANDOMENICO C, LEO S, TAFUTO S, GRECO E, ROSELLI M, MILIA V, MANCARELLA S, DI PINTO G, DE LUCA L, VESSIA G., GAMBARDELLA, Antonio, Comella, P, Massidda, B, Filippelli, G, Farris, A, Natale, D, Barberis, G, Maiorino, L, Palmeri, S, Cannone, M, Condemi, G, SOUTHERN ITALY COOPERATIVE ONCOLOGY, Group, COLLABORATORS CASARETTI, R, Sandomenico, C, Leo, S, Tafuto, S, Greco, E, Roselli, M, Milia, V, Gambardella, Antonio, Mancarella, S, DI PINTO, G, DE LUCA, L, and Vessia, G.

Published
2009

24. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer

Author

Di Bartolomeo, Maria, primary, Pietrantonio, Filippo, additional, Rulli, Eliana, additional, Poli, Davide, additional, Berenato, Rosa, additional, Caporale, Marta, additional, Bajetta, Emilio, additional, Floriani, Irene, additional, Bajetta, E., additional, Di Bartolomeo, M., additional, Catena, L., additional, Schiavo, M., additional, Pinotti, G., additional, Proserpio, I., additional, Rosati, G., additional, Bordonaro, R., additional, Cordio, S., additional, Burrafato, G., additional, Bochicchio, A.M., additional, Aieta, M., additional, Fazio, N., additional, Spada, F., additional, Amoroso, V., additional, Marini, G., additional, Soto Parra, H., additional, Novello, G., additional, Massidda, B., additional, Ionta, M.T., additional, Comandè, M., additional, Venezia, R., additional, Bertolini, A., additional, Menatti, E., additional, Zanlorenzi, L., additional, Colombo, A., additional, Iop, A., additional, Bonura, S., additional, Mazza, E., additional, Viganò, M., additional, Ardizzoia, A., additional, Dell'Oro, S., additional, Lo Re, G., additional, Santeufemia, D., additional, Buonadonna, A., additional, Luisi, D., additional, Ucci, G., additional, Di Lucca, G., additional, Bonetti, A., additional, Bergamo, F., additional, Alù, M., additional, Vastola, F., additional, Marchetti, P., additional, Corsi, D.C., additional, Massa, E., additional, Di Pinto, G., additional, Duro, M., additional, Oliani, C., additional, Franchini, M., additional, Inzoli, A., additional, Gebbia, N., additional, Repetto, L., additional, Rota, S., additional, Frontini, L., additional, Labianca, R., additional, Mosconi, S., additional, Quadri, A., additional, De Grossi, S., additional, Bidoli, P., additional, Cazzaniga, M.E., additional, Villa, F., additional, Foa, P., additional, Ferrari, D., additional, Aitini, E., additional, Rabbi, C., additional, Barni, S., additional, Petrelli, F., additional, Giordano, M., additional, Luchena, G., additional, Pirovano, M., additional, Nasisi, A., additional, Catalano, V., additional, Giordani, P., additional, Zaniboni, A., additional, Leone, F., additional, Ferrario, S., additional, Beretta, G.D., additional, Menichetti, E.T., additional, Conte, D., additional, Mari, D., additional, Giannicola, R., additional, Pierantoni, C., additional, Luporini, A.G., additional, Ragazzini, A., additional, Ravaioli, A., additional, Tassinari, D., additional, Nicolini, M., additional, Amadori, D., additional, Frassineti, G.L., additional, Turci, D., additional, Zumaglini, F., additional, Tamberi, S., additional, Piancastelli, A., additional, Cruciani, G., additional, Bejtja, E., additional, Falcone, A., additional, Landi, L., additional, Minuti, G., additional, Cantore, M., additional, Orlandi, M., additional, Mambrini, A., additional, Ciarlo, A., additional, Cavaciocchi, D., additional, Del Monte, F., additional, Ricci, S., additional, Brunetti, I.M., additional, Lencioni, M., additional, Sisani, M., additional, Sozzi, P., additional, Granetto, C., additional, Chiara, S., additional, Galetto, A.S., additional, Ribecco, A.S., additional, DeCensi, A., additional, Ciuffreda, L., additional, Baldini, E.E., additional, Camisa, R., additional, Todeschini, R., additional, Santoro, A., additional, Rimassa, L., additional, Carnaghi, C., additional, Pressiani, T., additional, Boni, C., additional, Rondini, E., additional, Gnoni, R., additional, Di Costanzo, F., additional, Gasperoni, S., additional, Cavanna, L., additional, Palladino, M.A., additional, Mattioli, R., additional, Laici, G., additional, Pucci, F., additional, Alessio, M.D., additional, Bernardini, I., additional, Tomasello, G., additional, Baldino, G., additional, Rossetti, R., additional, Giaquinta, S., additional, Pinto, C., additional, Di Fabio, F., additional, Rijas Llimpe, F.L., additional, Brandes, A.A., additional, Marzola, M., additional, Rummo Benevento, A.O.G., additional, Competiello, S., additional, Montesarchio, V., additional, Rea, A., additional, Daniele, B., additional, Genua, G., additional, Licenziato, M., additional, Casaretti, R., additional, Silvestro, L., additional, Montano, M., additional, Sarobba, M.G., additional, Sanna, G., additional, Filippelli, G., additional, Dima, G., additional, Greco, E., additional, Roselli, M., additional, Natale, D., additional, Condemi, G., additional, Fumi, G., additional, Tafuto, S., additional, Masullo, P., additional, Nitti, D., additional, Marchet, A., additional, Tiberio, G., additional, de Manzoni, G., additional, Nobili, S., additional, Fiorentini, G., additional, Mazzanti, R., additional, Perrotta, E., additional, Carlomagno, C., additional, De Stefano, A., additional, Cartenì, G., additional, and Otero, M., additional

Published
2016
Full Text
View/download PDF

26. P-263 - Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

Author

Avallone, A., Nasti, G., Rosati, G., Carlomagno, C., Romano, C., Bilancia, D., De Stefano, A., Silvestro, L., Ottaiano, A., Cassata, A., Bianco, F., Izzo, F., Delrio, P., De Gennaro, E., Casaretti, R., Tafuto, S., Albino, V., Pace, U., Lastoria, S., Gallo, C., Budillon, A., and Piccirillo, M.

Published
2018
Full Text
View/download PDF

27. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the Southern Italy Cooperative Oncology Group

Author

COMELLA P, CRUCITTA E, DE VITA, Ferdinando, DE LUCIA L, FARRIS A, DEL GAIZO F, PALMERI S, IANNELLI A, MANCARELLA S, TAFUTO S, MAIORINO L, BUZZI F, DE CATALDIS G, CASARETTI R, AVALLONE A, MONTELLA M, COMELLA G, CATALANO G, LORUSSO V, DE LENA M, BIGLIETTO M, SANNA G, SAROBBA MG, BELLI C, RUSSO A, PIZZARDI V, ACCURSO V, MUSCA A, GRAVINA A, LEOPALDI G, BRUNETTI C, MUCI D, LEO S, AVINO F, DE LUCA L, GRECO E, AIELLO C., ORDITURA, Michele, Comella, P, Crucitta, E, DE VITA, Ferdinando, DE LUCIA, L, Farris, A, DEL GAIZO, F, Palmeri, S, Iannelli, A, Mancarella, S, Tafuto, S, Maiorino, L, Buzzi, F, DE CATALDIS, G, Casaretti, R, Avallone, A, Montella, M, Comella, G, Orditura, Michele, Catalano, G, Lorusso, V, DE LENA, M, Biglietto, M, Sanna, G, Sarobba, Mg, Belli, C, Russo, A, Pizzardi, V, Accurso, V, Musca, A, Gravina, A, Leopaldi, G, Brunetti, C, Muci, D, Leo, S, Avino, F, DE LUCA, L, Greco, E, and Aiello, C.

Published
2002

28. ITACA-S (Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach) trial: comparison of a sequential treatment with irinotecan (cpt-11) + 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer

Author

Bajetta, E., Floriani, I., Di Bartolomeo, M., Labianca, R., Alfredo Falcone, Di Costanzo, F., Comella, G., Amadori, D., Martoni, A., Tortora, G., Nitti, D., Daniela, B., Mini, E., Rulli, E., Cropalato Di Tullio, M., Santoro, A., Casaretti, R., Boni, C., Pinotti, G., Bidoli, P., Rosati, G., Ravaioli, A., and Study Group, Cantore M. On Behalf Of Itaca S.

Published
2012

29. A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix®) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICOG trial 0802

Author

Casaretti, R., primary, Comella, P., additional, Carlomagno, C., additional, Maiorino, L., additional, Greco, E., additional, Russo, A., additional, Sanna, G., additional, Barzelloni, M.L., additional, Massidda, B., additional, Formica, V., additional, Serci, C., additional, Defraia, S., additional, Palmieri, G., additional, and Ionta, M.T., additional

Published
2015
Full Text
View/download PDF

30. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Bajetta, E, Floriani, I, Di Bartolomeo, M, Labianca, R, Falcone, A, Di Costanzo, F, Comella, G, Amadori, D, Pinto, C, Carlomagno, C, Nitti, D, Daniele, B, Mini, E, Poli, D, Santoro, A, Mosconi, S, Casaretti, R, Boni, C, Pinotti, G, Bidoli, P, Landi, L, Rosati, G, Ravaioli, A, Cantore, M, Di Fabio, F, Aitini, E, Marchet, A, Valsecchi, M, VALSECCHI, MARIA GRAZIA, Bajetta, E, Floriani, I, Di Bartolomeo, M, Labianca, R, Falcone, A, Di Costanzo, F, Comella, G, Amadori, D, Pinto, C, Carlomagno, C, Nitti, D, Daniele, B, Mini, E, Poli, D, Santoro, A, Mosconi, S, Casaretti, R, Boni, C, Pinotti, G, Bidoli, P, Landi, L, Rosati, G, Ravaioli, A, Cantore, M, Di Fabio, F, Aitini, E, Marchet, A, Valsecchi, M, and VALSECCHI, MARIA GRAZIA

Abstract

Some trial have demonstrated a benefit of adjuvant fluoropirimidine with or without platinum compounds compared with surgery alone. ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI [irinotecan plus 5-fluorouracil/folinic acid (5-FU/LV)] followed by docetaxel plus cisplatin improves disease-free survival in comparison with 5-FU/LV in patients with radically resected gastric cancer.

Published
2014

31. [Early evaluation using PET-FDG of the efficiency of neoadjuvant radiochemotherapy treatment in locally advanced neoplasia of the lower rectum]

Author

Delrio P, Lastoria S, Avallone A, Vincenzo Ravo, Guida C, Cremona F, Izzo F, Palaia R, Ruffolo F, Puppio B, Gm, Guidetti, Gl, Cascini, Casaretti R, Tatangelo F, Marone P, Gb, Rossi, Budillon A, Petrillo A, De Rosa V, Comella G, Morrica B, Tempesta A, Botti G, and Parisi V

Subjects
Organoplatinum Compounds, Rectal Neoplasms, Biopsy, Remission Induction, Leucovorin, Thiophenes, Neoadjuvant Therapy, Oxaliplatin, Treatment Outcome, Chemotherapy, Adjuvant, Fluorodeoxyglucose F18, Antineoplastic Combined Chemotherapy Protocols, Preoperative Care, Quinazolines, Humans, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Fluorouracil, Neoplasm Recurrence, Local, Radiopharmaceuticals, Tomography, Emission-Computed
Abstract

Preoperative chemoradiation allows downstaging of locally advanced rectal cancer and in selected patients also a sufficient downsizing to ensure sphincter preservation. Selection of patients warranting a preoperative approach is improved by magnetic resonance imaging (MRI) which is able to define the involvement of mesorectal circumferential margin. Similarly it would be crucial to define the response to chemoradiation during the treatment but traditional morphologic imaging techniques may fail in differentiating neoplastic tissue from scarring. PET-FDG has been successfully used in the detection of metastatic colorectal cancer allowing imaging of deposits as small as 0.5 cm and may have a role in evaluating early response to chemoradiation.In the present study, in patients with T3-T4 rectal cancer undergoing preoperative chemoradiation PET-FDG and flow cytometry analysis on endoscopic biopsy specimen have been performed before, during and after preoperative chemoradiation.Chemoradiation treatment has been successful in terms of downsizing and downstaging of the tumor. PET-FDG was able to demonstrate local response at only ten-fifteen days after the beginning of neoadjuvant therapy, also identifying non responding patients.FDG-PET may have a role in defining the response to chemoradiation and modulate the treatments strategy in patients with advanced rectal cancer.

Published
2003

36. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer: Tolerability and feasibility of a phase III study.

Author

Bajetta, E., primary, Floriani, I., additional, Di Bartolomeo, M., additional, Labianca, R., additional, Falcone, A., additional, Santoro, A., additional, Casaretti, R., additional, Pasquini, E., additional, Martoni, A., additional, and Carlomagno, C., additional

Published
2010
Full Text
View/download PDF

40. Oxaliplatin + Raltitrexed + Fufa and Preoperative Concomitant Radiotherapy for Locally Advanced Rectal Cancer: A Phase I-ii Study

Author

Avallone, A, primary, Delrio, P, additional, Ravo, V, additional, Marone, P, additional, Palaia, R, additional, Casaretti, R, additional, Rossi, GB, additional, Guida, C, additional, Petrillo, A, additional, Budillon, A, additional, Tempesta, A, additional, Lastoria, S, additional, Morrica, B, additional, Cornelia, G, additional, and Parisi, V, additional

Published
2002
Full Text
View/download PDF

43. Oxaliplatin (L-OHP) and irinotecan (CPT-11) with 6s-leucovorin (IFA)-modulated 5-fluorouracil (FU) i.v. bolus every 2 weeks: a dose-finding study in patients (pts) with gastrointestinal malignancies

Author

Comella, P., primary, De Vita, F., additional, De Lucia, L., additional, Crucitta, E., additional, Palmeri, S., additional, Casaretti, R., additional, Orditura, M., additional, Avallone, A., additional, Catalano, G., additional, and De Lena, M., additional

Published
2001
Full Text
View/download PDF

48. Biweekly administration of methotrexate (MTX), levofolinic acid (LFA), and 5-fluorouracil (5-FU) in advanced colorectal carcinomas

Author

Casaretti, R., primary, Comella, P., additional, Cartenl, G., additional, Manzione, L., additional, Biglietto, M., additional, De Lucia, L., additional, Daponte, A., additional, Gallipoli, A., additional, Caponigro, F., additional, Lorusso, V., additional, Palmieri, G., additional, Gravina, A., additional, and Comella, G., additional

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results